Aap Implantate AG Reports Annual Sales Growth Amidst Market Challenges

aap Implantate AG announced a preliminary annual sales of EUR 12.2 million for 2024, marking a 6% increase over the previous year. This growth was attributed mainly to strong performances across EMEA, LATAM, and APAC, although sales in North America declined by 19% due to restructuring efforts. However, North America showed signs of recovery by the end of the year with an 11% decrease in the fourth quarter compared to the previous year. The company's strategic investment in its aap systems contributed to an enhanced product mix, laying a foundation for continued expansion.

The company achieved several significant milestones in 2024, including completion of patient recruitment for its antibacterial implants study and success in initial MDR audits which are crucial for future certifications. Additionally, aap expanded its market reach particularly in the APAC region, while strengthening its equity through capital measures. Final audited results are expected to be released in April 2025.